Participated · Series G · Feb 2026

Varo Bank operates a fully digital, nationally chartered banking platform that has focused on the needs of everyday Americans since launching its app in 2017. The company offers a suite of products such as high-yield savings accounts, cashback debit cards, the Varo Believe secured card, Varo Advance, and the Varo Line of Credit. Its proprietary machine-learning models supplement traditional credit data, broadening access to credit beyond conventional scoring methods. In 2025, these lending products generated $547 million in loan volume, underscoring strong demand for Varo’s credit offerings. Management reports simultaneous revenue growth and cost reductions in 2025, demonstrating improved operating efficiency. Varo’s technology-first approach is reinforced by the governance and risk discipline required of a nationally chartered bank, and the company has earned recognition on the Inc. 5000, CNBC World’s Top Fintech Companies, Forbes’ World’s Best Banks, and Fast Company’s Most Innovative Companies lists. Recent additions to the board, including former Morgan Stanley CMO Alice Milligan and former JPMorgan executive Kevin Watters, bring additional financial industry expertise to guide the next stage of growth.

Participated · Series A · Apr 2023

Abdera leverages its Radio Optimized Vector Engineering (ROVEr™) platform to design heavy‑chain‑only, antibody‑based radiopharmaceuticals engineered for optimal pharmacokinetics and radioisotope delivery. The company aims to improve therapeutic index by pairing engineered antibodies with alpha or beta emitting isotopes to selectively destroy tumor cells while sparing healthy tissue. Abdera’s lead program targets DLL3 for small cell lung cancer and other solid tumors and is advancing through preclinical development with an IND expected in 2024. The company says it has generated promising proof‑of‑concept data across tumor models and is building a pipeline against additional undisclosed cancer targets. Abdera is led by an experienced team spanning biologics, radiochemistry and oncology drug development. The company is based in Menlo Park, California and Vancouver, British Columbia.

Led · Seed · May 2022

Total Flow Medical is developing a patent-pending arterial cannula that allows clinicians to provide blood flow to a patient’s lower leg during extracorporeal circulation. The device is intended to address unpredictable ischemic and reperfusion injuries that can occur during cardiopulmonary bypass procedures. The company recently completed a Seed financing that was originally sized at $3.5M and closed oversubscribed at $4.1M. Northview LifeSciences is participating in the Seed financing as lead investor. Proceeds from the raise will advance the company’s first product through regulatory approval in preparation for commercialization. The announcement did not disclose operating metrics or additional investors.

Participated · Equity · Nov 2015

CureVac develops medicines and vaccines using an optimized mRNA technology platform (RNAoptimizer) that aims to tailor protein design, mRNA optimization and mRNA delivery. The company is advancing prophylactic vaccines and mRNA-based therapeutics across infectious diseases, oncology and rare diseases. CureVac reported a Phase 1 clinical trial start for its SARS-CoV-2 vaccine candidate CVnCoV in June. The firm is investing in industrial-scale GMP production and is completing a fourth production site in Tübingen, Germany to expand manufacturing capacity. Headquartered in Tübingen, CureVac also has sites in Frankfurt and Boston. The EIB loan will support both clinical development and accelerated completion of the new production facility. CureVac AG is a Tübingen-based developer of drugs based on messenger RNA (mRNA) technology. Its proprietary platform uses mRNA as a data carrier to instruct the body to produce proteins; its programs include mRNA-based cancer immunotherapies, prophylactic vaccines against infectious diseases, molecular therapies to trigger production of therapeutic proteins, prolonged expression of functional antibodies and antibody-like proteins from mRNA, and an RNA-based adjuvant to enhance immunogenicity. The company was founded in 2000 as a spin-off from the University of Tübingen by Ingmar Hoerr, PhD, who is listed as CEO. CureVac has entered collaborations with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI. It has raised approximately $360M since inception and secured $29.5M in the financing announced in November 2016. The company intends to use the new funds to advance development of its mRNA product portfolio. CureVac is a clinical-stage biopharmaceutical company pioneering mRNA-based technologies to instruct the body to produce therapeutic proteins. The company focuses on natural, chemically unmodified mRNA product candidates including cancer immunotherapies, prophylactic vaccines (RNActive®), molecular therapies (RNArt®) and RNA-encoded antibodies (RNAntibody®). Its most advanced candidate, CV9104, is in Phase IIb for prostate cancer; other clinical programs include non-small cell lung cancer (partnered with Boehringer Ingelheim) and rabies, with additional programs targeting HIV, rotavirus, RSV and tuberculosis. CureVac will use the proceeds to further develop its clinical pipeline and to expand its proprietary mRNA platform technology. The company raised about $110M (€100m) in the reported round, bringing total capital to roughly $220M since founding in 2000. CureVac changed its corporate legal form from a GmbH to an AG to facilitate further international growth. CureVac develops a new class of therapies and vaccines based on mRNA, using its RNActive® therapeutic vaccine platform and RNAdjuvant long non-coding RNA adjuvants. The company is advancing two lead RNActive cancer vaccines targeting prostate cancer and non-small cell lung cancer (NSCLC). It has completed Phase 1/2a studies with its RNActive cancer vaccines in prostate cancer and NSCLC. CureVac also develops prophylactic vaccines and adjuvants for infectious diseases and collaborates with partners on development programs. Leadership includes CEO Ingmar Hoerr, Ph.D., and board chairman Friedrich von Bohlen, Ph.D. The company is based in Tübingen, Germany. CureVac GmbH develops RNActive® therapeutic vaccines targeting solid tumours and prophylactic vaccines against infectious diseases. Its lead therapeutic, CV9103 for prostate cancer, is in a Phase IIa trial with results expected in the second half of 2010. The company is also developing CV9201, an mRNA vaccine candidate for non-small cell lung cancer currently in Phase I. The recent financing will support further clinical development of the RNActive platform and accelerate preclinical and clinical work on prophylactic candidates. CureVac is a spin-off from Tübingen University and is based in Tübingen, Germany. Since its foundation the company has raised a total of €65m (US$83m).

Participated · Series A · Jul 2015

Perimeter Medical Imaging develops, patents, and commercializes high-resolution intraoperative imaging tools to allow clinicians to assess microscopic tissue structures during surgery. Its flagship OTIS™ (Optical Tissue Imaging System) provides an ultra-high resolution image of the entire surface of excised tissue, enabling real-time decisions at the surgical margin. OTIS™ is a platform technology designed to image multiple tissue types and aims to reduce follow-on surgeries—for example, roughly 25% of breast lumpectomy patients currently require a second operation due to residual cancer cells. Perimeter is a privately owned Canadian company and describes OTIS™ as an investigational device limited to investigational use under U.S. law. The company recently closed an oversubscribed $5 million Series A and will use proceeds to complete a clinical study at Princess Margaret Cancer Centre, advance product development, and pursue FDA regulatory clearance for its first tissue-imaging product.